Following Algeta and Clavis, is PCI the next big thing in cancer from Norway?
“Norwegian Medical Sensation: Removes cancer with light – The tumours almost fell off” ran the recent front page of Norwegian daily newspaper VG reporting the first results from PCI Biotech’s ongoing phase I/II study at University College Hospital (UCH) in London.

Viewpoint

By Werner Christie, MD. Chairman, Public Advice Asia, Beijing.

Former Norwegian health minister Dr Werner Christie is now heavily involved in promoting Sino-Norwegian life science collaboration. In the year of EXPO 2010 where life sciences and medtech will feature prominently in the Norwegian exhibit, he gives his personal view of the potential.

The latest from Nordiag, Algeta, Clavis, HUNT, GA, DiaGenic, Nutri Pharma/Bionor Immuno and Lytix.

Last year Algeta and Clavis put Norwegian cancer treatment innovation truly on the world map. Already in 2010, PCI Biotech is staking a strong claim to be the next shining light to emerge from what is becoming one of the hottest biotech spots in the world. Fresh from reporting extremely promising initial Phase I/II trial results for its lead product Amphinex®, CEO Per Walday explains the company’s background and goals.

The Nansen Neuroscience Network
Neuroscience, medtech and oncology are three areas in which Norway excels. Following the success of the Oslo Cancer Cluster, neuroscience seemed a natural choice for a similar model.

Following its granting of Arena status, the Kathrine Myhre and her team at Oslo Medtech Cluster have wasted no time in moving forward with announcing what promises to be an exciting year of events.

Unbeknown to many, the EU and Norway almost came to blows recently over mackerel, until MareLife came to the rescue with a unique genetic study of mackerel stocks that provided the basis for an agreement.

Overall 2009 proved to be an amazing year for Oslo Cancer Cluster. And 2010 has already got off to a flying start with the signing of a new collaboration agreement with the Hamner Institute in North Carolina.

The oceans have been good to Norway, not just for trade, fisheries and oil, but also increasingly providing a steady stream of biomarine ingredients such as Omega 3. Regenics is a young biotech company focusing on developing therapeutic wound healing products from proprietary biomarine extracts – initially salmon eggs.

Event Calendar
“Better City, Better Life” is the theme for the EXPO 2010, which is open from 1 May to 31 October 2010. A total of 70 million people are expected to visit EXPO 2010.